Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m 2 bid: Comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer

Hei Cheul Jeung, SunYoung Rha, Sang Joon Shin, Joong Bae Ahn, Sung Hoon Noh, Jae Kyung Roh, Hyuncheol Chung

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: In this study, we compared the pharmacokinetic profiles of 5-fluorouracil (5-FU), tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) after administration of S-1 at 35 or 40 mg/m. 2 bid for 28 consecutive days, in Cycles 1 and 3, in patients with advanced gastric cancer. Methods: Three patients were enrolled for each dosage. S-1 dosage was assigned based on body surface area (BSA), which is different from the Japanese dosing system. The median daily dose per BSA was 76 mg/m. 2 , ranging from 70 to 88 mg/m. 2 . Results: Plasma levels of 5-FU, tegafur, CDHP and Oxo at 4 h post-dose reached steady-state on day 8. The estimated steady-state level was dependent on S-1 dosage. There were no intercyclic differences of pre-dose and 4 h post-dose levels between Cycles 1 and 3, implying no cumulative effect of S-1 was shown probably due to 2-week drug-resting period. Pharmacokinetic profiles on day 28 were similar to previous Japanese report. C max and AUC 0-48 h values of each S-1 component increased depending on S-1 dosage. Pharmacokinetic parameters were not correlated with tumor response or toxicity. Conclusions: We suggest that these pharmacokinetic profiles of Asian population could provide a basis for schedule optimization and for additional studies on interaction with other antitumor drugs.

Original languageEnglish
Article numberhyp124
Pages (from-to)29-35
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume40
Issue number1
DOIs
Publication statusPublished - 2009 Oct 31

Fingerprint

Stomach Neoplasms
Pharmacokinetics
Tegafur
Body Surface Area
Fluorouracil
Antineoplastic Agents
Area Under Curve
Appointments and Schedules
Pharmaceutical Preparations
Population
Neoplasms
gimeracil

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

@article{c174ba16b0ea41698fe386ea25f035e1,
title = "Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m 2 bid: Comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer",
abstract = "Objective: In this study, we compared the pharmacokinetic profiles of 5-fluorouracil (5-FU), tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) after administration of S-1 at 35 or 40 mg/m. 2 bid for 28 consecutive days, in Cycles 1 and 3, in patients with advanced gastric cancer. Methods: Three patients were enrolled for each dosage. S-1 dosage was assigned based on body surface area (BSA), which is different from the Japanese dosing system. The median daily dose per BSA was 76 mg/m. 2 , ranging from 70 to 88 mg/m. 2 . Results: Plasma levels of 5-FU, tegafur, CDHP and Oxo at 4 h post-dose reached steady-state on day 8. The estimated steady-state level was dependent on S-1 dosage. There were no intercyclic differences of pre-dose and 4 h post-dose levels between Cycles 1 and 3, implying no cumulative effect of S-1 was shown probably due to 2-week drug-resting period. Pharmacokinetic profiles on day 28 were similar to previous Japanese report. C max and AUC 0-48 h values of each S-1 component increased depending on S-1 dosage. Pharmacokinetic parameters were not correlated with tumor response or toxicity. Conclusions: We suggest that these pharmacokinetic profiles of Asian population could provide a basis for schedule optimization and for additional studies on interaction with other antitumor drugs.",
author = "Jeung, {Hei Cheul} and SunYoung Rha and Shin, {Sang Joon} and Ahn, {Joong Bae} and Noh, {Sung Hoon} and Roh, {Jae Kyung} and Hyuncheol Chung",
year = "2009",
month = "10",
day = "31",
doi = "10.1093/jjco/hyp124",
language = "English",
volume = "40",
pages = "29--35",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "1",

}

Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m 2 bid : Comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer. / Jeung, Hei Cheul; Rha, SunYoung; Shin, Sang Joon; Ahn, Joong Bae; Noh, Sung Hoon; Roh, Jae Kyung; Chung, Hyuncheol.

In: Japanese Journal of Clinical Oncology, Vol. 40, No. 1, hyp124, 31.10.2009, p. 29-35.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m 2 bid

T2 - Comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer

AU - Jeung, Hei Cheul

AU - Rha, SunYoung

AU - Shin, Sang Joon

AU - Ahn, Joong Bae

AU - Noh, Sung Hoon

AU - Roh, Jae Kyung

AU - Chung, Hyuncheol

PY - 2009/10/31

Y1 - 2009/10/31

N2 - Objective: In this study, we compared the pharmacokinetic profiles of 5-fluorouracil (5-FU), tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) after administration of S-1 at 35 or 40 mg/m. 2 bid for 28 consecutive days, in Cycles 1 and 3, in patients with advanced gastric cancer. Methods: Three patients were enrolled for each dosage. S-1 dosage was assigned based on body surface area (BSA), which is different from the Japanese dosing system. The median daily dose per BSA was 76 mg/m. 2 , ranging from 70 to 88 mg/m. 2 . Results: Plasma levels of 5-FU, tegafur, CDHP and Oxo at 4 h post-dose reached steady-state on day 8. The estimated steady-state level was dependent on S-1 dosage. There were no intercyclic differences of pre-dose and 4 h post-dose levels between Cycles 1 and 3, implying no cumulative effect of S-1 was shown probably due to 2-week drug-resting period. Pharmacokinetic profiles on day 28 were similar to previous Japanese report. C max and AUC 0-48 h values of each S-1 component increased depending on S-1 dosage. Pharmacokinetic parameters were not correlated with tumor response or toxicity. Conclusions: We suggest that these pharmacokinetic profiles of Asian population could provide a basis for schedule optimization and for additional studies on interaction with other antitumor drugs.

AB - Objective: In this study, we compared the pharmacokinetic profiles of 5-fluorouracil (5-FU), tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) after administration of S-1 at 35 or 40 mg/m. 2 bid for 28 consecutive days, in Cycles 1 and 3, in patients with advanced gastric cancer. Methods: Three patients were enrolled for each dosage. S-1 dosage was assigned based on body surface area (BSA), which is different from the Japanese dosing system. The median daily dose per BSA was 76 mg/m. 2 , ranging from 70 to 88 mg/m. 2 . Results: Plasma levels of 5-FU, tegafur, CDHP and Oxo at 4 h post-dose reached steady-state on day 8. The estimated steady-state level was dependent on S-1 dosage. There were no intercyclic differences of pre-dose and 4 h post-dose levels between Cycles 1 and 3, implying no cumulative effect of S-1 was shown probably due to 2-week drug-resting period. Pharmacokinetic profiles on day 28 were similar to previous Japanese report. C max and AUC 0-48 h values of each S-1 component increased depending on S-1 dosage. Pharmacokinetic parameters were not correlated with tumor response or toxicity. Conclusions: We suggest that these pharmacokinetic profiles of Asian population could provide a basis for schedule optimization and for additional studies on interaction with other antitumor drugs.

UR - http://www.scopus.com/inward/record.url?scp=74949129707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949129707&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyp124

DO - 10.1093/jjco/hyp124

M3 - Article

C2 - 19880858

AN - SCOPUS:74949129707

VL - 40

SP - 29

EP - 35

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 1

M1 - hyp124

ER -